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Recombinant Human Proteoglycan-4 Mediates
Interleukin-6 Response in Both Human and
Mouse Endothelial Cells Induced Into a
Sepsis Phenotype
Holly A. Richendrfer, PhD1,2; Mitchell M. Levy, MD3; Khaled A. Elsaid, PharmD, PhD4;
Tannin A. Schmidt, PhD5; Ling Zhang, MD1,2; Ralph Cabezas, BS1,2; Gregory D. Jay, MD, PhD1,2
Objectives: Sepsis is a leading cause of death in the United States.
Putative targets to prevent systemic inflammatory response syndrome
include antagonism of toll-like receptors 2 and 4 and CD44 receptors
in vascular endothelial cells. Proteoglycan-4 is a mucinous glycoprotein that interacts with CD44 and toll-like receptor 4 resulting in a
blockade of the NOD-like receptor pyrin domain-containing-3 pathway. We hypothesized that endothelial cells induced into a sepsis
phenotype would have less interleukin-6 expression after recombinant human proteoglycan 4 treatment in vitro.
Design: Enzyme-linked immunosorbent assay and reverse transcriptase-quantitative polymerase chain reaction to measure interleukin-6
protein and gene expression.
Setting: Research laboratory.
Subjects: Human umbilical vascular endothelial cells, human lung
microvascular endothelial cells, and transgenic mouse (wild type)
(Cd44+/+/Prg4+/+), Cd44–/– (Cd44tm1HbgPrg4+/+), Prg4GT/GT (Cd44+/+
Prg4tm2Mawa/J), and double knockout (Cd44tm1Hbg Prg4tm2Mawa/J) lung
microvascular endothelial cells.
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Interventions: Cells were treated with 100 or 250 ng/mL lipopolysaccharide-Escherichia coli K12 and subsequently treated with
recombinant human proteoglycan 4 after 30 minutes. Interleukin-6
levels in conditioned media were measured via enzyme-linked immunosorbent assay and gene expression was measured via reverse
transcriptase-quantitative polymerase chain reaction with ΔΔ–Ct
analysis. Additionally, human umbilical vascular endothelial cells and
human lung microvascular endothelial cells were treated with 1:10
diluted plasma from 15 patients with sepsis in culture media. After 30
minutes, either 50 or 100 µg/mL recombinant human proteoglycan
4 was administered. Interleukin-6 protein and gene expression were
assayed. Proteoglycan 4 levels were also compared between control
and sepsis patient plasma.
Measurements and Main Results: Human umbilical vascular endothelial
cell, human lung microvascular endothelial cell, and mouse lung microvascular endothelial cell treated with lipopolysaccharide had significantly
increased interleukin-6 protein compared with controls. Recombinant
human proteoglycan-4 significantly reduced interleukin-6 in human and
mouse endothelial cells. Interleukin-6 gene expression was significantly
increased after lipopolysaccharide treatment compared with controls.
This response was reversed by 50 or 100 µg/mL recombinant human
proteoglycan-4 in 80% of sepsis samples in human umbilical vascular
endothelial cells and in 60–73% in human lung microvascular endothelial
cells. In Cd44–/– genotypes of the mouse lung microvascular endothelial
cells, recombinant human proteoglycan-4 significantly reduced interleukin-6 protein levels after lipopolysaccharide treatment, indicating that
Cd44 is not needed for recombinant human proteoglycan-4 to have an
effect in a toll-like receptor 4 agonist inflammation model. Patient sepsis
samples had higher plasma levels of native proteoglycan-4 than controls.
Interpretation and Conclusions: Recombinant human proteoglycan-4
is a potential adjunct therapy for sepsis patients and warrants future
in vivo model studies.
Key Words: CD44; cytokines; inflammation; proteoglycan-4; sepsis;
toll-like receptors

DOI: 10.1097/CCE.0000000000000126

Critical Care Explorations

www.ccejournal.org

1

Richendrfer et al

S

epsis is the body’s immune response to infection in major
organs including the lung, urinary tract, blood, and skin structures. More than 1.5 million people are diagnosed with sepsis
in the United States every year and roughly 250,000 of those patients
die due to multiple organ failure with a mortality rate around 33%
(1). Antibiotics treat the initiating cause of sepsis but effective treatments intended to blunt immune cell dysfunction are needed.
The body’s immune response during sepsis is extensive and
includes the up-regulation of pro-inflammatory cytokines, caspases, C-reactive protein, procalcitonin, and transcription factors
(2, 3). One of the commonly used biomarkers in sepsis is the cytokine interleukin (IL)-6, which is thought to be indicative of the most
severe cases of sepsis and is upregulated in inflammatory cellular
pathways (4). IL-6 is a glycoprotein that is released from many different cell types during the immune reaction in response to pathogen-associated molecular patterns or damage-associated molecular
patterns (5–8). Because it is noted as a severe sepsis biomarker (4,
8), we chose to focus on the IL-6 response in the current study. At
present, there is still no effective treatment that is able to target and
counteract the intense immune response during sepsis, making the
condition difficult to treat and stabilize (9). Previously the toll-like
receptor (TLR)-4 antagonist resatorvid Tak242, a cyclohexene derivative, showed promise in a phase 2 trial (NCT00143611) in patients
with acute sepsis but was unable to advance to phase 3 due to iatrogenic methemoglobinemia caused by this small molecule (10).
Lubricin (proteoglycan-4 [PRG4]; genebank number NM_005807)
is a mucin-like 224 kDa glycoprotein originally found as a lubricating substance within the synovial fluid of diarthrodial joints (11–15).
More recently, it has been found in other tissues including lung, liver,
brain, heart, bladder, bone, eye, uterus, cervix, and prostate indicating that it serves a multifunctional role (16–18). Lubricin has recently
been implicated as an anti-inflammatory mediator in innate immunity pathways (19–21), and CD44 (21–23) has been conceptualized
to play a role in its entry into the cytoplasm thereby pointing to its
role as a potential adjunct treatment in sepsis. Full-length recombinant human PRG4 (rhPRG4) has been used in limited clinical trials
in xerophthalmia and no adverse effects were recorded (24, 25).
Lipopolysaccharide, a potent agonist of the TLRs, was used in this
work to recapitulate inflammatory triggers in vitro in endothelial cells
that are observed in sepsis (26). We used both lipopolysaccharide and
plasma from culture-negative and culture-positive sepsis patients to
initiate a strong IL-6 response in human umbilical vascular endothelial cells (HUVECs) and human lung microvascular endothelial cells
(HLMVECs). Lipopolysaccharide was also used to treat transgenic
mouse lung microvascular endothelial cells (MLMVEC) that were
Cd44 sufficient or null. After lipopolysaccharide or patient plasma
treatment, cell culture samples were treated with rhPRG4 in order
to determine if IL-6 gene expression and protein levels were altered.
The results of the current study indicate that rhPRG4 is a potential
therapeutic that can be used to reverse the inflammatory response
commonly seen in sepsis. Additionally, using transgenic MLMVECs,
we show that rhPRG4 reduced IL-6 levels in both the presence and
absence of the CD44 receptor and endogenous Prg4, indicating that
CD44 may not be required in facilitating anti-inflammatory activity
in these cells, especially in regard to TLR4 ligands. Lastly, PRG4 levels
in sepsis patient plasma were assayed and compared with controls.
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MATERIALS AND METHODS
Patient Samples
Patient plasma samples were obtained from Sepsis, [Extracorporeal Membrane Oxygentation], and [Acute Respiratory
Distress Syndrome] biobank patients at Rhode Island Hospital
under institutional review board protocol number 4116-16 and
used to treat both HUVEC and HLMVEC. Patient demographics are shown in Supplementary Table 1 (Supplemental Digital
Content 1, http://links.lww.com/CCX/A181).
Supplementary Materials and Methods (Supplemental Digital
Content 2, http://links.lww.com/CCX/A182) provide additional
information.

RESULTS
Enzyme-Linked Immunosorbent Assay IL-6 Protein
Concentrations
HUVEC Culture—Lipopolysaccharide Treatment. Media from
untreated control HUVECs had baseline levels of IL-6 protein of
60.6 ± 1.0 pg/mL. Lipopolysaccharide treatment increased IL-6
protein levels to 671.6 ± 53.39 pg/mL and was significantly higher
from media untreated controls (p < 0.001) (Fig. 1A). IL-6 protein levels were significantly reduced by 5–150 µg/mL rhPRG4
30 minutes after cells were treated with lipopolysaccharide. After
lipopolysaccharide treatment, 5 µg/mL rhPRG4 reduced IL-6
levels 32% to 459.9 ± 75.18 pg/mL (p < 0.01), 10 µg/mL rhPRG4
reduced IL-6 levels 48% to 350.0 ± 22.0 pg/mL (p < 0.001), 25
µg/mL rhPRG4 reduced IL-6 levels 88% to 77.7 ± 2.7 pg/mL
(p < 0.001), 50 µg/mL rhPRG4 reduced IL-6 levels 91% to 63.84
± 1.4 pg/mL (p < 0.001), 100 µg/mL rhPRG4 reduced IL-6 levels 94% to 43.1 ± 1.1 pg/mL (p < 0.001), and 150 µg/mL rhPRG4
reduced IL-6 levels 84% to 106.7 ± 15.8 pg/mL (p < 0.001). Cells
treated with 25 or 150 µg/mL rhPRG4 alone had IL-6 levels that
were not statistically different from untreated controls.
HLMVEC Culture—Lipopolysaccharide Treatment. Media
from untreated control HLMVECs had baseline levels of IL-6 that
were 277.9 ± 23.3 pg/mL. Lipopolysaccharide treatment increased
IL-6 levels to 2,733.5 ± 85.4 pg/mL which was significantly higher
compared with media from untreated controls (p < 0.001) (Fig.
1B). After 30 minutes of lipopolysaccharide treatment 25, 50, and
100 µg/mL rhPRG4 reduced IL-6 levels 79% to 566.8 ± 26.2, 87%
to 349.0 ± 15.7, and 91% to 242.0 ± 10.3 pg/mL (p < 0.001 for all
when compared with lipopolysaccharide). Cells treated with 150
µg/mL rhPRG4 alone had IL-6 levels that were not significantly
different from untreated controls.
HUVEC Culture—Patient Plasma Treatment. Eighty percent
of sepsis patient plasma samples lowered IL-6 levels significantly
following treatment with 50 µg/mL rhPRG4 (p < 0.05) (Fig. 2). As
a positive control, lipopolysaccharide significantly increased IL-6
levels to 385.7 ± 18.9 pg/mL from 13.6 ± 4.0 pg/mL media levels
(p < 0.001) which was reversed with rhPRG4 treatment 97% to
10.3 ± 2.5 pg/mL (p < 0.001) (data not shown). IL-6 values shown
in Figure 2 were normalized by subtracting background levels of
IL-6 from patient plasma.
2020 • Volume 2 • e0126
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Figure 2. Patient sepsis samples used in human umbilical vascular
endothelial cell (HUVEC) culture. HUVEC culture treated with 100 µL of
patient plasma and 900 µL media prior to 50 µg/mL recombinant human
proteoglycan-4 (rhPRG4) treatment for 23.5 hr. Data from patient samples
represent normalized interleukin (IL)-6 levels corrected for native levels
of IL-6. Unpaired t tests within patient samples were used to determine
significance. Data presented are mean + sem. *p < 0.05, **p < 0.01,
***p < 0.001. Treatment with 250 ng/mL lipopolysaccharide served as a
positive control and resulted in an IL-6 level of 385.7 ± 18.9 pg/mL (data
not shown). NS = not significant, sea = Sepsis, [Extracorporeal Membrane
Oxygentation], and [Acute Respiratory Distress Syndrome].

Figure 1. Concentration-dependent effect of recombinant human
proteoglycan-4 (rhPRG4) on interleukin (IL)-6 production in
lipopolysaccharide (LPS) stimulated human umbilical vascular endothelial
cells (HUVEC) and human lung microvascular endothelial cells (HLMVEC).
IL-6 protein concentrations measured via enzyme-linked immunosorbent
assay after LPS followed by rhPRG4 treatment in HUVECs (A) and
HLMVECs (B). Cells were treated with 250 ng/mL LPS for 30 min prior
to rhPRG4 treatment for 23.5 hr. Data presented are mean + sem. *p <
0.05, **p < 0.01, ***p < 0.001; all groups compared with LPS IL-6 values
using analysis of variance with Dunnett post hoc comparison. NS = not
significant.

Figure 3. Patient sepsis samples used in human lung microvascular endothelial
cell (HLMVEC) culture and treated with recombinant human proteoglycan-4
(rhPRG4) at a low concentration. HLMVEC culture treated with 100 µL of
patient plasma and 900 µL media prior to 50 µg/mL rhPRG4 treatment for
23.5 hr. Data from patient samples represent normalized interleukin (IL)-6 levels
corrected for native levels of IL-6. Unpaired t tests within patient samples were
used to determine significance. Data presented are mean + sem. *p < 0.05, **p
< 0.01, ***p < 0.001. Treatment with 250 ng/mL lipopolysaccharide served as
a positive control and resulted in a IL-6 level of 1,318.0 ± 14.4 pg/mL (data
not shown). NS = not significant, sea = Sepsis, [Extracorporeal Membrane
Oxygentation], and [Acute Respiratory Distress Syndrome].

HLMVEC Culture—Patient Plasma Treatment. Sixty percent of
sepsis patient plasma samples lowered IL-6 levels significantly following treatment with 50 µg/mL rhPRG4 (p < 0.05) (Fig. 3). One sepsis patient plasma sample increased IL-6 following treatment with
rhPRG4 treatment (p < 0.05, SEA 22). Lipopolysaccharide significantly increased IL-6 protein levels from 96.3 ± 0.8 pg/mL in media

controls to 1,318.0 ± 14.4 pg/mL (p < 0.001) which was decreased
81% to 248.9 ± 11.7 pg/mL by 50 µg/mL rhPRG4 (p < 0.001)
(data not shown). The IL-6 values shown in Figure 3 were normalized
by subtracting background levels of IL-6 from patient plasma.
Lipopolysaccharide significantly increased IL-6 protein levels
from 67.1 ± 2.6 pg/mL in media controls to 765.9 ± 12.6 pg/mL
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(p < 0.001) which was decreased 75% to 193.4 ± 2.2 pg/mL by
100 µg/mL rhPRG4 (p < 0.001) (data not shown). Seventythree percent of sepsis patient plasma samples lowered IL-6 levels significantly following treatment with 100 µg/mL rhPRG4
(p < 0.05) (Fig. 4). Twenty percent of sepsis patient plasma samples increased IL-6 levels significantly following treatment with
100 µg/mL rhPRG4 (SEA 4, SEA 23, and SEA 24). The IL-6 values
shown in Figure 4 were normalized by subtracting background
levels of IL-6 from patient plasma.
MLMVEC Culture—Lipopolysaccharide Treatment. In wild
type MLMVECs (Cd44+/+ Prg4+/+), lipopolysaccharide significantly
increased IL-6 protein levels to 307.5 ± 23.7 pg/mL compared with
media controls at 12.8 ± 5.3 pg/mL (p < 0.001) (Fig. 5A). However,
all groups co-treated with both lipopolysaccharide and rhPRG4
had significantly reduced IL-6 levels compared with the lipopolysaccharide control group. Compared with the lipopolysaccharide
only treated cells, those subsequently treated with 50, 100, and 150
µg/mL rhPRG4 had significantly reduced IL-6 levels that were lowered 26% to 227.3 ± 4.9 pg/mL (p < 0.01), 69% to 94.4 ± 23.3 pg/mL
(p < 0.001), and 66% to 105.4 ± 10.1 pg/mL (p < 0.001).
In MLMVECs that were null for Cd44 (Cd44tm1Hbg Prg4+/+),
lipopolysaccharide treatment significantly increased IL-6 protein levels to 145.1 ± 15.1 pg/mL compared with media controls
measured at 2.3 ± 0.8 pg/mL (p < 0.001) (Fig. 5B). There was no
change in IL-6 in cells treated with lipopolysaccharide and then
subsequently treated with 50 µg/mL rhPRG4. However, compared
with the lipopolysaccharide only group, cells subsequently treated

with 100 and 150 µg/mL rhPRG4 had significantly reduced IL-6
levels that were lowered 62% to 55.4 ± 16.1 pg/mL (p < 0.001) and
58% to 60.9 ± 17.2 pg/mL (p < 0.01).
MLMVECs that were null for Prg4 (Cd44+/+ Prg4tm2Mawa/J) and
treated with lipopolysaccharide had significantly increased IL-6
levels measured at 237.0 ± 4.2 pg/mL compared with media controls at 8.5 ± 3.1 pg/mL (p < 0.001) (Fig. 5C). Cells treated with
lipopolysaccharide and then subsequently treated with 50 µg/mL
rhPRG4 did not differ in IL-6 levels compared with lipopolysaccharide treated cells. However, compared with the lipopolysaccharide only group, cells subsequently treated with 100 and 150 µg/
mL rhPRG4 had significantly reduced IL-6 levels that were lowered 49% to 120.6 ± 3.5 pg/mL and 55% to 105.5 ± 11.3 pg/mL
(p < 0.001 for both groups).
In MLMVECs that were double knockout (Cd44tm1Hbg
Prg4tm2Mawa/J), cells treated with lipopolysaccharide had significantly increased IL-6 levels measured at 167.5 ± 17.1 pg/mL in
comparison to media controls at 2.5 ± 0.7 pg/mL (p < 0.001)
(Fig. 5D). Cells treated with lipopolysaccharide and subsequently
treated with 50, 100, and 150 µg/mL rhPRG4 had significantly
reduced IL-6 compared with lipopolysaccharide only treated cells
that were lowered 32% to 113.0 ± 3.1 pg/mL (p < 0.01), 78% to 36.2
± 10.7 pg/mL (p < 0.001), and 80% to 33.5 ± 2.4 pg/mL (p < 0.001).
Supplementary Figure 1 (Supplemental Digital Content 3, http://
links.lww.com/CCX/A183; legend, Supplemental Digital Content
7, http://links.lww.com/CCX/A187), Supplementary Figure 2
(Supplemental Digital Content 4, http://links.lww.com/CCX/
A184; legend, Supplemental Digital
Content 7, http://links.lww.com/
CCX/A187), Supplementary Figure
3 (Supplemental Digital Content
5,
http://links.lww.com/CCX/
A185; legend, Supplemental Digital
Content 7, http://links.lww.com/
CCX/A187), Supplementary Figure
4 (Supplemental Digital Content 6,
http://links.lww.com/CCX/A186;
legend, Supplemental Digital Content
7,
http://links.lww.com/CCX/
A187), and Supplementary Results
(Supplemental Digital Content 8,
http://links.lww.com/CCX/A188)
provide additional information.

DISCUSSION

Figure 4. Patient sepsis samples used in human lung microvascular endothelial cell (HLMVEC) culture and
treated with recombinant human proteoglycan-4 (rhPRG4) at a high concentration. HLMVEC culture treated
with 100 µL of patient plasma and 900 µL media prior to 100 µg/mL rhPRG4 treatment for 23.5 hr. Data from
patient samples represent normalized interleukin (IL)-6 levels corrected for native levels of IL-6. Unpaired t tests
within patient samples were used to determine significance. Data presented are mean + sem. *p < 0.05,
**p < 0.01, ***p < 0.001. Treatment with 250 ng/mL lipopolysaccharide served as a positive control and resulted
in an IL-6 level of 765.9 ± 12.6 pg/mL (data not shown). NS = not significant, sea = Sepsis, [Extracorporeal
Membrane Oxygentation], and [Acute Respiratory Distress Syndrome].
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The TLR family includes many
members each playing interrelated
roles in host defense mechanisms
during the immune response (27).
Lipopolysaccharide is a strong agonist of the TLRs and upon binding,
results in an inflammatory cascade
within the cell, leading to the release
of cytokines and chemokines, including IL-6 (28, 29). The majority of the
culture-positive clinical isolates used
2020 • Volume 2 • e0126
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with lipopolysaccharide in the current study. Furthermore, the results
of the current study show that even
though lipopolysaccharide elicited a
significant increase of IL-6 protein levels and gene expression in HUVECs,
HLMVECs, and MLMVECs these
levels were reversed by rhPRG4 in a
concentration-dependent
manner.
Although this study is the first of its
kind to use endothelial cells treated
with rhPRG4, the results indicate that
rhPRG4 has strong anti-inflammatory
properties consistent with similar
studies in other cell types, pointing to
an anti-inflammatory role of lubricin
(19–23). These studies indicate that
PRG4 has two biological mechanisms
of action within the cell in order to
counteract inflammation.
Both native human PRG4 (nhPRG4)
and rhPRG4 were found to bind to and
act as an antagonist to TLR2 and TLR4
receptors in the human embryonic kidney-293 reporter cell line which was
verified using enzyme-linked immunosorbent assay, flow cytometry, and
immunoprecipitation (19). nhPRG4
was also able to block activation of
Figure 5. Interleukin (IL)-6 levels from transgenic mouse lung microvascular endothelial cells after
both TLR2 and TLR4 after the agolipopolysaccharide (LPS) and recombinant human proteoglycan-4 (rhPRG4) treatments. IL-6 protein
nists synthetic triacylated lipoprotein
concentrations measured via enzyme-linked immunosorbent assay after 100 ng/mL LPS and rhPRG4 treatment
in wild-type (Cd44+/+ Prg4+/+) (A), Cd44 null (Cd44tm1Hbg Prg4+/+) (B), Prg4 null (Cd44+/+ Prg4tm2Mawa/J) (C), and
and lipopolysaccharide were used, furdouble knockout (DKO) (Cd44tm1Hbg Prg4tm2Mawa/J) (D). Cells were treated with LPS for 30 min prior to rhPRG4
ther supporting the role of PRG4 as an
treatment for 23.5 hr. Data presented are mean + sem. *p < 0.05, **p < 0.01, ***p < 0.001; all groups compared
anti-inflammatory biologic (19). These
with LPS IL-6 values using analysis of variance with Dunnett post hoc comparison. NS = not significant.
results fall in line with the results of our
current study in that rhPRG4 competes with lipopolysaccharide in
in this study contained lipopolysaccharide by virtue of the presence of Escherichia coli. The glycoprotein IL-6 is released from a concentration-dependent manner in order to prevent and reverse
inflammation because the addition of rhPRG4 in our experiments
many cell types, including endothelial cells (30), as a result of
occurred “after” cells were exposed to lipopolysaccharide. In using
tissue injury or pathogen invasion. It is a ubiquitous biomarker
of severe sepsis in both neonates and adults (4, 6–8, 31–35). MLMVECs that were null for Cd44, there remained a reduction in
IL-6 following rhPRG4 treatment, indicating that its anti-inflamTherefore, we chose to evaluate IL-6 protein and gene expression
matory properties are not dependent on an interaction with CD44.
in the current study as a representation of a sepsis-like response by
Overall, endothelial cells that were Cd44 null (Cd44tm1HbgPrg4+/+ and
mouse and human endothelial cells. Endothelial cells were chosen
because their function is highly affected during sepsis (36). Barrier Cd44tm1HbgPrg4GT/GT) showed a net lower level of IL-6 upon exposure
function, signal transduction, vasoregulation, and blood coagula- to lipopolysaccharide indicating that animals sufficient for Cd44 may
tion are all affected by endothelial cells due to their intimal locahave greater inflammatory effects from an induced cellular sepsis
tion in blood vessels (36). Dyscrasias in endothelial cells caused by
response. We also observed in Figure 5 that rhPRG4 is more effective
sepsis plays a major role in blood vessel permeability, acidosis, and than the endothelial cell’s native Prg4 in lowering IL-6.
coagulopathy. Macrophages were not studied in this investigation
Inflammatory cascades within many cell types, including endoas we have already shown that NOD-like receptor pyrin domainthelial cells, are also activated via activation of the CD44 receptor. If
containing-3 (NLRP3) is inhibited by rhPRG4 in a human leukethe inflammatory cascades are activated within the cell, the NLRP3
mia monocytic cell line THP-1 cells (21).
inflammasome becomes activated and nuclear factor kappa-lightThe lipopolysaccharide used in the current study was the E.
chain-enhancer of activated B cells (NF-κB) nuclear translocation
occurs, both of which drive cytokine release from the cell (21, 22,
coli K12-ultrapure variety which only activates TLR4 receptors.
Levels of IL-6 protein and gene expression significantly increased 37–40). Previous studies indicate that rhPRG4 blocks NF-κB transloin HUVECs, HLMVECs, and MLMVECs after cells were treated cation and prevents activation of the NLRP3 inflammasome after it is
Critical Care Explorations
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internalized in the cell (22). The results from that study indicated that
aside from the well-known agonist, hyaluronic acid, rhPRG4 is also a
ligand for the CD44 receptor and binds with a higher affinity than HA
(22). However, rhPRG4 still showed anti-inflammatory properties in
endothelial cells null for Cd44. Therefore, it is possible that rhPRG4
exerted its effects via a different mechanism, such as inactivation of
TLR4 and possible cellular internalization via other receptor-mediated and nonreceptor mediated pathways.
Based upon the results of the current study and previous studies, it appears that rhPRG4 may be useful as an adjunct therapeutic for a variety of disorders with an immune reaction, including
sepsis by either antagonizing TLR2 and TLR4, as was recently
reviewed (41). Although a CD44 dependent mechanism in endothelial cells was not observed, this cell surface receptor may still be
involved in other immune cells such as macrophages (21). TLR2
and TLR4 have been antagonized in the past in clinical studies
using small molecules (10) which appeared promising but eluded
translation. PRG4 is normally present in the serum in low levels
as it is expressed by hepatocytes and many other organ systems
(16–18, 42). In our study, sepsis patients showed higher overall
PRG4 levels in plasma in comparison to control patients which
indicate that PRG4 may act as an antagonist in the sepsis response
in humans (Supplementary Results, Supplemental Digital Content
8, http://links.lww.com/CCX/A188). However, there was no
within-subject correlation between IL-6 and PRG4 levels in sepsis
patient plasma which could be due to the timing of plasma collection and sepsis severity. In a mouse sepsis model, an organ-based
proteomics study (43) indicated that both protein and transcript
levels of Prg4 were upregulated in the liver suggesting it may act
as an antagonist of the sepsis response in a murine model as well.
When endothelial cells were treated with plasma from septic patients,
the results of IL-6 protein levels and gene expression (Supplementary
Results, Supplemental Digital Content 8, http://links.lww.com/CCX/
A188) did not share the same magnitude of change as the results from
cells treated with only lipopolysaccharide. This may have been due to
our RNA collection timepoint at 24 hours post lipopolysaccharide and
rhPRG4 treatment or due to the array of inflammatory factors in the
septic plasma. Plasma from septic patients can contain either grampositive and negative bacterial components and a variety of cytokines.
These components can further amplify inflammation as measured in
our assays via interaction with tumor necrosis factor receptor, CD44,
and other targets which may explain why rhPRG4 did not decrease
IL-6 protein and gene expression in all cell samples treated with septic patient plasma (44–49). Furthermore, it is also possible that gene
expression analysis should have been performed at an earlier timepoint than 24 hours post-treatment with patient plasma due to the
latency between upregulated gene expression and subsequent protein
release. For example, it has been reported that peak cytokine release
occurs between 2 and 6 hours post lipopolysaccharide administration
in macrophages and liver tissue (50–52). Unfortunately, due to limitations on patient plasma availability, only one timepoint was used for
both protein and RNA analysis in our study.
As far as limitations of our study, we believe this study is relevant
to the early stages of sepsis that are lipopolysaccharide dependent.
Sepsis is a complicated disease process that takes time to evolve; as it
does, a biomolecule like PRG4 theoretically becomes less effective.
6
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Ongoing work on additional patient samples will be conducted in
order to study endothelial cell gene expression at earlier sepsis timepoints post lipopolysaccharide and rhPRG4 treatment in vitro. We
are presently also using an in vivo mouse model to test the effects of
rhPRG4 in an lipopolysaccharide-induced sepsis model.

CONCLUSIONS

Based upon the data presented in the current study, innate
immune cellular responses of IL-6 from HUVECs, HLMVECs,
and MLMVECs can be reversed by treatment with rhPRG4.
Therefore, we believe that rhPRG4 is deserving of additional study
as a potential adjunct therapeutic for sepsis patients.
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